



(51) International Patent Classification:

C12N 15/00 (2006.01) C07K 1/00 (2006.01)
C12N 9/16 (2006.01) C07H 21/04 (2006.01)

(21) International Application Number:

PCT/US2014/066375

(22) International Filing Date:

19 November 2014 (19.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/906,374 19 November 2013 (19.11.2013) US

(71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, Massachusetts 02138 (US).

(72) Inventors: CHAVEZ, Alejandro; 108 Sewall Avenue, Unit 4, Brookline, Massachusetts 02446 (US). POELWIJK, Franck; 7482 Walling Lane, Dallas, Texas 75231 (US). CHURCH, George M.; 218 Kent Street, Brookline, Massachusetts 02446 (US).

(74) Agent: IWANICKI, John P.; 28 State Street, Suite 1800, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: MUTANT CAS9 PROTEINS

FIG. 1



(57) Abstract: Methods of making deletion mutants of Cas9 proteins and making chimeric Cas9 proteins are described. The Cas9 N- and C-terminal domains may play critical roles in crRNA/tracrRNA binding and/or PAM selectivity. To analyze activity, a series of domain exchange mutants between NM and STI (*Streptococcus thermophilus* Cas9) were made, replacing the N and/or C terminus of NM (*Neisseria meningitidis* Cas9) with the homologous region from STI. The chimeric proteins were then tested using the transcriptional reporter assay described herein altering the guideRNA and/or Cas9 specific PAM within the reporter to determine the influence of the domain exchanges on protein specificity. None of the N- terminal domain swaps between NM and STI endowed NM with novel properties. The C-terminal exchange generated a NM-STI hybrid that was capable of interacting with the STI crRNA/tracrRNA complex and was further able to suppress a reporter with a STI specific PAM.

MUTANT CAS9 PROTEINS

RELATED APPLICATION

This application claims priority to U.S. Provisional Patent Application No. 61/906,374, filed on November 19, 2013 and is hereby incorporated herein by reference in its entirety for all purposes.

STATEMENT OF GOVERNMENT INTERESTS

This invention was made with government support under Grant No. P50 HG005550 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

Bacterial and archaeal CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* 471, 602-607 (2011); Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proceedings of the National Academy of Sciences of the United States of America* 109, E2579-2586 (2012); Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337, 816-821 (2012); Sapranas, R. et al. The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic acids research* 39, 9275-9282 (2011); and Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. *Annual review of genetics* 45, 273-297 (2011). A recent *in vitro* reconstitution of the *S. pyogenes* type II CRISPR system demonstrated that crRNA ("CRISPR RNA") fused to a normally trans-encoded tracrRNA ("trans-activating CRISPR RNA") is sufficient to direct Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA. Expressing a gRNA homologous to a target site results in Cas9 recruitment and degradation of the target DNA. See H. Deveau et al., Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *Journal of Bacteriology* 190, 1390 (Feb, 2008).

Cas9 is a DNA nuclease that can be programmed to target nearly any region of a genome by expressing a guide RNA (gRNA) that contains a motif that recruits Cas9 and 20 basepairs of complementarity to a region of the genome where targeting is desired. All characterized and putative Cas9 family members are several kilobases in size (>3,000 basepairs) with the smallest

functionally validated member NM-Cas9 (*Neisseria meningitides* Cas9) being 3,249 basepairs in size. The large size of this protein limits its potential for biotechnology and therapeutic applications due to difficulties of delivery and manipulation.

SUMMARY

5 Aspects of the present disclosure are directed to an RNA guided DNA binding protein of a Type II CRISPR System that binds to the DNA and is guided by the one or more RNAs which has been engineered to omit portions of the protein while still functioning as an RNA guided DNA binding nuclease that can bind to target DNA and create a double stranded break in target DNA. According to one aspect, the RNA guided DNA binding protein of a Type II CRISPR System is a
10 Cas9 protein.

Aspects of the present disclosure are directed to an RNA guided DNA binding protein of a Type II CRISPR System which has been engineered to omit portions of the protein while still functioning as an RNA guided DNA binding nickase that can bind to target DNA and create a single stranded break or nick in target DNA. According to one aspect, the RNA guided DNA
15 binding protein of a Type II CRISPR System is a Cas9 protein.

Aspects of the present disclosure are directed to an RNA guided DNA binding protein of a Type II CRISPR System which has been engineered to omit portions of the protein while still functioning as an RNA guided DNA binding protein which is nuclease null, that is, the RNA guided DNA binding protein lacks nuclease activity. According to one aspect, the RNA guided
20 DNA binding protein of a Type II CRISPR System is a Cas9 protein.

According to one aspect, portions of an RNA guided DNA binding protein are identified for deletion by identifying within a population of species of the RNA guided DNA binding protein sequences which are not well conserved or are otherwise highly divergent within a particular RNA guided DNA binding protein family and/or protein sequences between boundaries between low and
25 high conservation referred to herein as “conservation edges” within a particular RNA guided DNA binding protein family. According to this aspect, amino acid sequences within a DNA binding protein, such as an RNA guided DNA binding protein, such as Cas9, are identified as having either high conservation or low conservation using methods described herein and as are known to those of skill in the art. According to one aspect, amino acid sequences of high conservation and amino
30 acid sequences of low conservation are adjacent, such as immediately adjacent, to one another within the protein sequence of the DNA binding protein as a whole. The amino acid sequences of high conservation and the amino acid sequences of low conservation are distinguished by an amino acid which separates an amino acid sequence of high conservation from an amino acid sequence of low conservation. In this manner, the amino acid which separates an amino acid sequence of high
35 conservation from an amino acid sequence of low conservation is referred to herein as an “edge

amino acid” or a “conservation edge” to the extent that it is at an edge or terminal portion of either an amino acid sequence of high conservation or an amino acid sequence of low conservation. Accordingly, the methods of the present disclosure contemplate identifying an amino acid which separates an amino acid sequence of high conservation from an amino acid sequence of low conservation or otherwise distinguishes an amino acid sequence of high conservation from an amino acid sequence of low conservation. Such an amino acid is referred to herein as an “edge amino acid.” According to this aspect, a pair of edge amino acids may flank or bound on either end an amino acid sequence of high conservation. Likewise, a pair of edge amino acids may flank or bound on either end an amino acid sequence of low conservation. Still according to this aspect, one exemplary embodiment relates to the identification within the protein sequence of a DNA binding protein as a whole, adjacent amino acid sequences of high conservation and amino acid sequences of low conservation. In particular, one exemplary embodiment relates to the identification within the protein sequence of a DNA binding protein as a whole, sequences of high conservation in tandem or in series with sequences of low conservation, and in particular, a sequence of high conservation (HC) bounded on either end by a sequence of low conservation (LC) or alternatively a sequence of low conservation (LC) bounded on either end by a sequence of high conservation (HC). In this manner, exemplary tandem sequences or sequences in series identified by the methods described herein may be schematically depicted as LC-HC-LC or HC-LC-HC. According to this aspect, a middle sequence of either high conservation or low conservation is bounded by flanking sequences of either low conservation or high conservation, respectively. In the exemplary tandem sequence LC-HC-LC, a pair of edge amino acids distinguish or separate the amino acid sequence of high conservation (HC) from the two flanking amino acid sequences of low conservation (LC) which are on either end of or otherwise bound the amino acid sequence of high concentration. In the exemplary tandem sequence HC-LC-HC, a pair of edge amino acids distinguish or separate the amino acid sequence of low conservation (LC) from the two flanking amino acid sequences of high conservation (HC) which are on either end of or otherwise bound the amino acid sequence of low conservation. When such an exemplary tandem sequence is identified using the methods described herein, whether the middle sequence is either an amino acid sequence of high conservation or an amino acid sequence of low conservation, the middle sequence is removed to create a mutant DNA binding protein according to the methods described herein which retains DNA binding activity and which is smaller in size compared to the wild type DNA binding protein. The edge amino acids define the middle sequence to be removed by flanking the middle sequence or otherwise separating the middle sequence from adjacent sequences in series to create the mutant DNA binding protein. According to certain aspects of the present disclosure, a middle sequence in the tandem sequences can be removed regardless of whether the middle sequence is an

amino acid sequence of high conservation or an amino acid sequence of low conservation insofar as the mutant DNA binding protein retains useful DNA binding protein activity.

In order to identify sequences which are not well conserved or protein sequences between conservation edges within the context of this disclosure, an alignment was obtained from PFAM or otherwise created from a collection of sequences resulting from a database search of Cas9 homologs. This alignment was computationally conditioned and the conservation was calculated as the per position (relative) entropy of amino acid frequencies. The sequences are then removed from the RNA guided DNA binding protein to produce a mutant.

According to one aspect, in order to identify regions within the multi-domain Cas9 protein that may be amenable to deletion, a bioinformatics approach is used to identify potential domain boundaries in the Cas9 proteins. A multiple sequence alignment is created by re-aligning Cas9 sequences in the PFAM database (PF13395) using MUSCLE, and the alignment is computationally conditioned for diversity and full-length sequences. The sequence conservation is calculated as the relative entropy of observed amino acid frequencies with respect to the average frequencies across all genes in *Escherichia coli*. A multi-scale edge filter (difference of Gaussians (DoG) band-pass filter) is applied to the conservation profile to assign potential protein domain boundaries referred to herein as conservation edges. Regions in between the conservation edges are selected for deletion in the first iteration of deletion mutants.

According to certain aspects, the present disclosure describes synthetic NM-Cas9 deletion mutants that are smaller in size yet retain near wild-type protein activity. The synthetic NM-Cas9 deletion mutants can be used to bind to DNA as a co-localization complex with guide RNA in a cell and create a double stranded break, a single stranded break or to locate an effector group near target DNA of interest to perform a desired function.

According to certain aspects an alignment-based domain detection method is provided to identify regions of a DNA binding protein, such as Cas9, that are dispensable for binding to DNA, and which can be removed to form a mutant DNA binding protein that is smaller in size compared to the wild type DNA binding protein. According to methods described herein, minimized Cas9 variants are generated that show robust activity in bacteria and human cells. According to aspects described herein, mutant functional DNA binding protein variants, such as mutant functional Cas9 variants, which are smaller than wild type DNA binding proteins, are provided.

According to certain aspects, exemplary DNA binding proteins include Cas9 orthologs such as *Neisseria meningitidis* Cas9 (NM, GI:218767588) and *Streptococcus thermophilus* Cas9 (ST1, GI:116627542) which have been shown to function in both prokaryotes and higher eukaryotes. See Hou, Z. *et al.* Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*. *Proceedings of the National Academy of Sciences of the United*

States of America 110, 15644-15649, doi:10.1073/pnas.1313587110 (2013) hereby incorporated by reference in its entirety.

These exemplary Cas9 orthologs are smaller in gene size compared to *Streptococcus pyogenes* Cas9 (SP, GI:13622193), i.e. about 3200 versus 4100 base pairs. Aspects of the present disclosure are therefore directed to reducing the size of a Cas9 DNA binding protein so as to increase the efficiency with which the Cas9 DNA binding protein can be delivered, particularly using viral packaging technologies where gene length can greatly influence viral titer. See Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the packaging limit of lentiviral vectors. *Human gene therapy* 12, 1893-1905, doi:10.1089/104303401753153947 (2001); Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. *Molecular therapy : the journal of the American Society of Gene Therapy* 18, 80-86, doi:10.1038/mt.2009.255 (2010); and Gelinas, C. & Temin, H. M. Nondefective spleen necrosis virus-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses. *Proceedings of the National Academy of Sciences of the United States of America* 83, 9211-9215 (1986) each of which is hereby incorporated in its entirety.

Synthetically reducing the size of Cas9 genes allow for more complex regulatory systems and functional domains to be packaged within single vectors. According to an additional aspect, methods are provided to synthetically alter PAM specificity allowing for the generation of smaller Cas9 variants with increased targeting potential.

According to certain aspects, methods are provided for making Cas9 chimera by exchanging the C-terminal domain of a first species of Cas9 with the C-terminal domain of a second species of Cas9. According to one aspect, the present disclosure provides domain exchange Cas9 chimera, such as a functional NM-ST1-Cas9 chimera, by exchanging the C-terminal domain of NM with ST1. The chimeric Cas9 protein exhibits ST1 guideRNA and PAM specificity.

According to one aspect, the cell is a prokaryotic cell or a eukaryotic cell. According to one aspect, the cell is a bacterial cell, a yeast cell, a plant cell or an animal cell. According to one aspect, the cell is a mammalian cell.

According to one aspect, the RNA is between about 10 to about 500 nucleotides. According to one aspect, the RNA is between about 20 to about 100 nucleotides.

According to one aspect, the one or more RNAs is a guide RNA. According to one aspect, the one or more RNAs is a crRNA. According to one aspect, the one or more RNAs is a tracrRNA. According to one aspect, the one or more RNAs is a tracrRNA-crRNA fusion.

According to one aspect, the target DNA is genomic DNA, mitochondrial DNA, viral DNA, conjugatable element or exogenous DNA.

According to one aspect, the RNA guided DNA binding protein is of a Type II CRISPR System that binds to the DNA and is guided by the one or more RNAs. According to one aspect,

the RNA guided DNA binding protein is a Cas9 protein that binds to the DNA and is guided by the one or more RNAs.

Further features and advantages of certain embodiments of the present invention will become more fully apparent in the following description of embodiments and drawings thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The foregoing and other features and advantages of the present invention will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings in which:

Fig. 1 is an image in which *E. coli* cells contain a YFP reporter for NM-Cas9 activity and are transformed with various NM-Cas9 nuclease null genes. In the absence of NM-Cas9, the cells are fluorescent (upper right quadrant-Negative control) and in the presence of full length nuclease null NM-Cas9 the cells are non-fluorescent (upper left quadrant-Positive control). Two of the generated NM-Cas9 deletions are shown, NM-Cas9- Δ 255-449 shows near wild-type levels of repression (bottom left quadrant) and NM-Cas9- Δ 874-922 shows lack of most DNA binding capacity (bottom right quadrant).

Fig. 2 is a phylogenetic tree as described in Fonfara I, et al., (2014) Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems, *Nucleic Acids Res.* 42, 2577-90 hereby incorporated by reference in its entirety. Marked in red are sequences used as an initial seed for the PFAM realignment.

Fig. 3 is a conservation profile of Cas9 alignment after truncation to positions of NM-Cas9.

Fig. 4 is a conservation profile truncated to positions in SP-Cas9.

Fig. 5A is a plot of first-order amino acid conservation within Cas9 proteins. Relative entropies are calculated with respect to the average amino acid frequency across all genes in *Escherichia coli*. Vertical lines above plot represent boundaries determined by the alignment-based boundary detection algorithm, with bold lines representing the six most significant boundaries detected. Fig. 5B shows domain assignments based on Fonfara, I. et al. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic acids research* 42, 2577-2590, doi:10.1093/nar/gkt1074 (2014) hereby incorporated by reference in its entirety. RuvCI-III are the parts folding into the RuvC nuclease domain. HNH is the HNH nuclease domain. RRR is the arginine-rich alpha-helical region. Cross-hatched is the extension of this region based on the arginine-rich stretch around position 140.

Fig. 6A is a schematic depicting design of NM Cas9 transcriptional reporter. The location of the protospacer and NM specific PAM are noted. Fig. 6B is a graph of NM Cas9 transcriptional repression assay data with various nuclease null NM mutants tested in *E. coli*. Data represent mean $\pm$ standard deviation (n=4). Fig. 6C is a schematic depicting NM Cas9 domain structure. White boxes with dashed outlines give the extent of the largest excised regions from NM mutants that cause minimal alteration in DNA binding activity.

Fig. 7 is directed to NM Cas9 deletion analysis and depicts design of NM Cas9 transcriptional reporter. The location of the protospacer and NM specific PAM are noted. NM Cas9 transcriptional repression assay with various nuclease null NM mutants were tested in *E. coli*. Data represent mean $\pm$ standard deviation (n=5).

Fig. 8A depicts ST1 Cas9 deletion analysis and functional validation in *E. coli* and human cells and in particular, design of ST1 Cas9 transcriptional reporter. The location of the protospacer and ST1 specific PAM are noted. ST1 Cas9 transcriptional repressor assay with ST1 nuclease-null deletion mutants tested in *E. coli*. Data represent mean $\pm$ standard deviation (n=4). Fig. 8B is a schematic depicting reporter construct for testing ST1 activation which contains a minimal CMV promoter (min CMV) upstream of a tdTomato reporter. ST1 nuclease null Cas9-VP64 fusion proteins binding upstream of the minimal CMV promoter lead to transcriptional activation and fluorescence within human cells. Fig. 8C are images of cells transfected with ST1 activators including deletion mutants were transfected along with sgRNAs and the tdTomato reporter and were visualized by fluorescence microscopy. Fig. 8D is a graph showing quantification of ST1 activation from panel C by flow cytometry. Data represent mean $\pm$ standard deviation (n=3).

Fig. 9 is directed to TD Cas9 deletion analysis and functional validation in *E. coli*. TD nuclease-null deletion mutants were tested using a transcriptional repressor assay. Data represent mean $\pm$ standard deviation (n=4).

Fig. 10A is directed to NM-ST1 domain swap analysis as determined by a transcriptional repression assay and in particular, design of NM and ST1 transcriptional reporters with the sequence of the NM or ST1 specific PAM illustrated. Fig. 10B is a schematic depicting outline of NM and ST1 Cas9 with the location of the amino acid swap points noted. Fig. 10C-10F are graphs of fluorescence for NM-ST1 nuclease null domain exchange mutants expressed in conjunction with guideRNAs particular to NM (Fig. 10C and Fig. 10D) or ST1 Cas9 (Fig. 10E and Fig. 10F), along with reporters with PAM sequences specific to either NM (Fig. 10C and Fig. 10F) or ST1 Cas9 (Fig. 10D and Fig. 10E). Data represent mean $\pm$ standard deviation (n=4).

Fig. 11A is directed to NM-ST1 domain swap analysis as determined by a transcriptional repression assay, and in particular, design of ST1 transcriptional reporter with the sequence of the ST1 specific PAM illustrated. Fig. 11B is a schematic outline of NM and ST1 Cas9 with the location of the amino acid swap points noted. Fig. 11C-11D are graphs of fluorescence for NM-

ST1 nuclease null domain exchange mutants expressed in conjunction with guide RNAs particular to NM (Fig. 11D) or ST1 Cas9 (Fig. 11C) along with reporters with PAM sequences specific to ST1 Cas9 (Fig. 11C and 11D). Data represent mean $\pm$ standard deviation (n=4).

DETAILED DESCRIPTION

5 Embodiments of the present invention are directed to mutant RNA guided DNA binding proteins of the Type II CRISPR system. Such mutants are created by removing sequences that are not well conserved or are otherwise highly divergent among species within a genus of RNA guided DNA binding proteins of the Type II CRISPR system. According to one aspect, the sequences of species within a family of RNA guided DNA binding proteins are aligned and sequences of low
10 conservation or sequences between conservation edges are determined. These sequences are then deleted from a particular RNA guided DNA binding protein. Exemplary RNA guided DNA binding proteins include Cas9 proteins present, for example, in Type II CRISPR systems. Such Cas9 proteins and Type II CRISPR systems are well documented in the art. See Makarova et al., *Nature Reviews, Microbiology*, Vol. 9, June 2011, pp. 467-477. The mutant DNA binding proteins
15 described herein can be used to make double stranded cuts in target DNA, single stranded cuts in target DNA or to bind to target DNA in a manner to locate an effector group near the target DNA such that that effector group can interact with the target DNA. Such effector groups include activators, repressors or epigenetic modifiers known to those of skill in the art.

 Exemplary DNA binding proteins having nuclease activity function to nick or cut double
20 stranded DNA. Such nuclease activity may result from the DNA binding protein having one or more polypeptide sequences exhibiting nuclease activity. Such exemplary DNA binding proteins may have two separate nuclease domains with each domain responsible for cutting or nicking a particular strand of the double stranded DNA. Exemplary polypeptide sequences having nuclease activity known to those of skill in the art include the McrA-HNH nuclease related domain and the
25 RuvC-like nuclease domain. Accordingly, exemplary DNA binding proteins are those that in nature contain one or more of the McrA-HNH nuclease related domain and the RuvC-like nuclease domain.

 According to one aspect, a DNA binding protein having two or more nuclease domains may be modified or altered to inactivate all but one of the nuclease domains. Such a modified or
30 altered DNA binding protein is referred to as a DNA binding protein nickase, to the extent that the DNA binding protein cuts or nicks only one strand of double stranded DNA. When guided by RNA to DNA, the DNA binding protein nickase is referred to as an RNA guided DNA binding protein nickase.

 An exemplary DNA binding protein is an RNA guided DNA binding protein of a Type II
35 CRISPR System. An exemplary DNA binding protein is a Cas9 protein.

In *S. pyogenes*, Cas9 generates a blunt-ended double-stranded break 3bp upstream of the protospacer-adjacent motif (PAM) via a process mediated by two catalytic domains in the protein: an HNH domain that cleaves the complementary strand of the DNA and a RuvC-like domain that cleaves the non-complementary strand. See Jinke et al., *Science* 337, 816-821 (2012) hereby
 5 incorporated by reference in its entirety. Cas9 proteins are known to exist in many Type II CRISPR systems including the following as identified in the supplementary information to Makarova et al., *Nature Reviews, Microbiology*, Vol. 9, June 2011, pp. 467-477: *Methanococcus maripaludis* C7; *Corynebacterium diphtheriae*; *Corynebacterium efficiens* YS-314; *Corynebacterium glutamicum* ATCC 13032 Kitasato; *Corynebacterium glutamicum* ATCC 13032
 10 Bielefeld; *Corynebacterium glutamicum* R; *Corynebacterium kroppenstedtii* DSM 44385; *Mycobacterium abscessus* ATCC 19977; *Nocardia farcinica* IFM10152; *Rhodococcus erythropolis* PR4; *Rhodococcus jostii* RHA1; *Rhodococcus opacus* B4 uid36573; *Acidothermus cellulolyticus* 11B; *Arthrobacter chlorophenolicus* A6; *Kribbella flavida* DSM 17836 uid43465; *Thermomonospora curvata* DSM 43183; *Bifidobacterium dentium* Bd1; *Bifidobacterium longum*
 15 DJO10A; *Slackia heliotrinireducens* DSM 20476; *Persephonella marina* EX H1; *Bacteroides fragilis* NCTC 9434; *Capnocytophaga ochracea* DSM 7271; *Flavobacterium psychrophilum* JIP02 86; *Akkermansia muciniphila* ATCC BAA 835; *Roseiflexus castenholzii* DSM 13941; *Roseiflexus* RS1; *Synechocystis* PCC6803; *Elusimicrobium minutum* Pei191; uncultured Termite group 1 bacterium phylotype Rs D17; *Fibrobacter succinogenes* S85; *Bacillus cereus* ATCC 10987;
 20 *Listeria innocua*; *Lactobacillus casei*; *Lactobacillus rhamnosus* GG; *Lactobacillus salivarius* UCC118; *Streptococcus agalactiae* A909; *Streptococcus agalactiae* NEM316; *Streptococcus agalactiae* 2603; *Streptococcus dysgalactiae* equisimilis GGS 124; *Streptococcus equi* zooepidemicus MGCS10565; *Streptococcus gallolyticus* UCN34 uid46061; *Streptococcus gordonii* Challis subst CH1; *Streptococcus mutans* NN2025 uid46353; *Streptococcus mutans*; *Streptococcus*
 25 *pyogenes* M1 GAS; *Streptococcus pyogenes* MGAS5005; *Streptococcus pyogenes* MGAS2096; *Streptococcus pyogenes* MGAS9429; *Streptococcus pyogenes* MGAS10270; *Streptococcus pyogenes* MGAS6180; *Streptococcus pyogenes* MGAS315; *Streptococcus pyogenes* SSI-1; *Streptococcus pyogenes* MGAS10750; *Streptococcus pyogenes* NZ131; *Streptococcus thermophiles* CNRZ1066; *Streptococcus thermophiles* LMD-9; *Streptococcus thermophiles* LMG
 30 18311; *Clostridium botulinum* A3 Loch Maree; *Clostridium botulinum* B Eklund 17B; *Clostridium botulinum* Ba4 657; *Clostridium botulinum* F Langeland; *Clostridium cellulolyticum* H10; *Fingoldia magna* ATCC 29328; *Eubacterium rectale* ATCC 33656; *Mycoplasma gallisepticum*; *Mycoplasma mobile* 163K; *Mycoplasma penetrans*; *Mycoplasma synoviae* 53; *Streptobacillus moniliformis* DSM 12112; *Bradyrhizobium* BTAi1; *Nitrobacter hamburgensis* X14;
 35 *Rhodopseudomonas palustris* BisB18; *Rhodopseudomonas palustris* BisB5; *Parvibaculum lavamentivorans* DS-1; *Dinoroseobacter shibae* DFL 12; *Gluconacetobacter diazotrophicus* Pal 5

FAPERJ; *Gluconacetobacter diazotrophicus* Pal 5 JGI; *Azospirillum* B510 uid46085; *Rhodospirillum rubrum* ATCC 11170; *Diaphorobacter* TPSY uid29975; *Verminephrobacter eiseniae* EF01-2; *Neisseria meningitidis* 053442; *Neisseria meningitidis* alpha14; *Neisseria meningitidis* Z2491; *Desulfovibrio salexigens* DSM 2638; *Campylobacter jejuni* doylei 269 97; 5 *Campylobacter jejuni* 81116; *Campylobacter jejuni*; *Campylobacter lari* RM2100; *Helicobacter hepaticus*; *Wolinella succinogenes*; *Tolomonas auensis* DSM 9187; *Pseudoalteromonas atlantica* T6c; *Shewanella pealeana* ATCC 700345; *Legionella pneumophila* Paris; *Actinobacillus succinogenes* 130Z; *Pasteurella multocida*; *Francisella tularensis* novicida U112; *Francisella tularensis* holarctica; *Francisella tularensis* FSC 198; *Francisella tularensis* tularensis; *Francisella* 10 *tularensis* WY96-3418; and *Treponema denticola* ATCC 35405. Accordingly, aspects of the present disclosure are directed to a mutant of a Cas9 protein present in a Type II CRISPR system, such as any one of the species identified above. An exemplary Cas9 protein is that found in *Neisseria meningitidis*, such as *Neisseria meningitidis* 053442; *Neisseria meningitidis* alpha14; *Neisseria meningitidis* Z2491.

15 Cells according to the present disclosure include any cell into which foreign nucleic acids can be introduced and expressed as described herein. It is to be understood that the basic concepts of the present disclosure described herein are not limited by cell type. Cells according to the present disclosure include eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, archaeal cells, eubacterial cells and the like. Cells include eukaryotic cells such as yeast cells, plant 20 cells, and animal cells. Particular cells include mammalian cells. Particular cells include stem cells, such as pluripotent stem cells, such as human induced pluripotent stem cells.

Target nucleic acids include any nucleic acid sequence to which a mutant RNA guided DNA binding protein nuclease can be useful to nick or cut. Target nucleic acids include genes. For purposes of the present disclosure, DNA, such as double stranded DNA, can include the target 25 nucleic acid and a co-localization complex can bind to or otherwise co-localize with the DNA at or adjacent or near the target nucleic acid and in a manner in which the co-localization complex may have a desired effect on the target nucleic acid. Such target nucleic acids can include endogenous (or naturally occurring) nucleic acids and exogenous (or foreign) nucleic acids. One of skill based on the present disclosure will readily be able to identify or design guide RNAs and mutant Cas9 30 proteins which co-localize to a DNA including a target nucleic acid. DNA includes genomic DNA, mitochondrial DNA, viral DNA, a conjugatable element or exogenous DNA.

Foreign nucleic acids (i.e. those which are not part of a cell's natural nucleic acid composition) may be introduced into a cell using any method known to those skilled in the art for such introduction. Such methods include transfection, transduction, viral transduction, 35 microinjection, lipofection, nucleofection, nanoparticle bombardment, transformation, conjugation

and the like. One of skill in the art will readily understand and adapt such methods using readily identifiable literature sources.

According to one aspect, the genetic material required to encode a Cas9 protein is reduced by deleting portions of the Cas9 protein which are not well conserved or otherwise diverge within species within a family of Cas9 or are between conservation edges within species within a family of Cas9. By reducing the size of the nucleic acid required to encode a functioning Cas9, additional nucleic acids can be included with a vector designed to deliver the Cas9, such as nucleic acids encoding guide RNA or regulatory elements or effector domains. If one uses the smallest characterized Cas9 family member, ~4,500 kilobases of DNA will be required to encode for the necessary genetic elements (Cas9 protein and gRNA) in order to properly localize Cas9 to the desired genomic locus. At ~4,500 basepairs Cas9 is near the size limit for packaging within AAV based viral vector (which is a regulatory approved viral vector in Europe.) Further, some of the first transcriptional and epigenetic effector domains to be fused to programmable DNA binding proteins are greater than 2,000 basepairs and thus far out of the packaging limit for AAV vectors and approaching the limit of lentiviral packaging systems (~8,000 basepairs) once fused to Cas9.

The following examples are set forth as being representative of the present disclosure. These examples are not to be construed as limiting the scope of the present disclosure as these and other equivalent embodiments will be apparent in view of the present disclosure, figures and accompanying claims.

EXAMPLE I

Mutant Cas9

To overcome the issues of large gene size encoding Cas9, a targeted deletion is carried out of various regions within one of the smallest characterized Cas9 family member NM-Cas9 (Neisseria meningitidis Cas9). NM-Cas9 is 3,249 bp in size. Requirements for targeting to the genome and the residues involved in nuclease activity are determined. To generate versions of NM-Cas9 which are smaller in size, an alignment of Cas9 proteins was generated and contiguous stretches of low conservation or stretches between conservation edges were identified for deletion. Several regions of interest were identified and selectively removed from NM-Cas9 which was then assessed for function by using a Cas9 repressor assay. In the assay, a variant of NM-Cas9 was used that lacks nuclease activity but is able to be targeted to the 5' region of a reporter gene. If NM-Cas9 is able to bind to the reporter gene it will repress transcription and in the case of a fluorescent reporter, the cells will appear non-fluorescent.

Cas9 alignment and deletion prediction: Full length sequences of Cas9 homologs were obtained either from the PFAM database or from a database search such as jackHMMER (R.D. Finn, J. Clements, S.R. Eddy, *Nucleic Acids Research* (2011) Web Server Issue 39:W29-W37 hereby incorporated by reference in its entirety). In case the collection of sequences is not aligned, an alignment is created using an alignment algorithm such as CLUSTALW (Sievers F, Wilm A, Dineen DG, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG (2011) hereby incorporated by reference in its entirety), or equivalent. The alignment was computationally cut to the positions of the sequence of interest and conditioned to diminish alignment bias (e.g. sequences with a greater than 95% pairwise identity were removed). Conservation is calculated as the entropy or relative entropy of amino acid frequencies per position, taking into account the amount of amino acids and gaps at that position. Deletions are targeted towards regions of low conservation or between conservation edges. In iterations with experimental verification, the deletions are expanded or shifted.

Deletion construction and characterization: Bacterial plasmids expressing nuclease null NM-Cas9 were previously generated as described in Esvelt, K. M., Mali, P., Braff, J. L., Moosburner, M., Yaung, S. J., and Church, G. M. (2013) *Nat Methods* 10, 1116-1121 hereby incorporated by reference in its entirety. To create targeted deletions within NM-Cas9, Gibson assembly was employed as described in Gibson, D. G., Young, L., Chuang, R. Y., Venter, J. C., Hutchison, C. A., 3rd, and Smith, H. O. (2009) *Nat Methods* 6, 343-345 hereby incorporated by reference in its entirety. Primers containing overlapping complementarily and which are designed to remove targeted regions within NM-Cas9 along with inserting a SGGGS linker were purchased and used in PCR reactions. PCR fragments were gel purified, assembled in vitro using Gibson assembly and transformed into *E. coli*. Clones were sequence verified and tested using a modified form of previously generated NM-Cas9 reporter plasmids (See (2013) *Nat Methods* 10, 1116-1121) in which a single plasmid (instead of two) contains the NM-Cas9 spacer, targeted protospacer and YFP reporter for NM-Cas9 activity. Briefly, in this assay cells are co-transformed with synthetic NM-Cas9 variants and the reporter plasmid. The doubly transformed cells are then grown up at 37°C, and the amount of YFP fluorescence is measured using a fluorescence plate reader and compared to cells that are transformed with a control plasmid with wild-type nuclease null NM-Cas9 and the reporter plasmid.

The below sequences are for the two largest NM-Cas9 single deletion mutants that retained near wild-type levels of activity as determined by the YFP reporter assay. The sequence of the SGGGS linker which replaces the deleted regions within NM-cas9 is shown in CAPS.

NM-Cas9-Δ255-449

atggccgccttcaagcccaacccatcaactacatcctgggcctggccatcgccatcgccagcgtgggctgggccatggtggagatcgacgaggacgagaacccatctgcctgatcgacctgggtgtgcgcgtgttcgagcgcgctgaggtgccaagactggtgacagtctggctatggct

cgccggcttgctcgtctgttcggcgcccttactgccggcgcgctcaccgcttctgcgcgctgccgctgtgaagcgcgaggggtgtgctg
 caggctgccgacttcgacgagaacggcctgatcaagagcctgcccaacactccttggcagctgcgcgctgccgctctggaccgcaagctga
 ctctcttgagtgaggcgcgctgctgctgcacctgatcaagcaccgcggctacctgagccagcgcaagaacgagggcgagaccgccgaca
 aggagctgggtgctctgtgaagggcgctggccgacaacgccacgccctgcagactggtgacttccgcactcctgctgagctggccctgaa
 5 caagttcgagaaggagagcggccacatccgcaaccagcgcggcgactacagccacacctcagccgcaaggacctgcaggccgagctga
 tcctgctgttcgagaagcagaaggagttcggaacccccacgtgagcggcggcctgaaggaggcgatcgagacctgctgatgaccagc
 gccccgccctgagcggcgacgccgtgcagaagatgTCCGGCGGCGGTTTCGggcgaccactacggcaagaagaacaccgag
 gagaagatctacctgcctcctatccccgccgacgagatccgcaaccccggtggtgctgcgcgccctgagccaggccccgcaaggtgatcaacg
 gctggtgctgcgcgtacggcagccccgccgcatccacatcgagaccgcccgcgaggtgggcaagagcttaaggaccgcaaggagatc
 10 gagaagcggcaggaggagaaccgcaaggaccgcgagaaggccgcccgaagtccgcgagtacttccccaaacttcgtggcgagcccaa
 gagcaaggacatcctgaagctgcgcctgtacgagcagcagcagcgaagtgcctgtacagcggcaaggagatcaacctggggccgctgaa
 cgagaagggtactgtggagatcgccgctgccctgcccttcagccgcacctgggacgacagcttcaacaacaaggctgctggtgctgggcagc
 gaggtcagaacaagggaaccagacccccctacgagtacttcaacggcaaggacaacagccgcgagtggcaggagttaaggcccgct
 ggagaccagccgcttccccgcagcaagaagcagcgcacatcctgctgcagaagttcgacgaggacggcttcaaggagcgcaacctgaacga
 15 caccgctacgtgaaccgcttctgtgccagttcgtggccgaccgcatgcgcctgaccggcaagggaagaagcgcgtgttcgccagcaac
 ggccagatcaccaacctgctgcgcggcttctggggcctgcgaaggtgcgcgccgagaacgaccgccaccacgccctggacgccgtggt
 ggtggcctgcagcaccgtggccatgcagcagaagatcacccgcttcgtgcgtacaaaggagatgaacgccttcgacggtaaaaccatcgac
 aaggagaccggcgaggtgctgcaccagaagaccacttccccagccctgggagttcttcgccaggaggtgatgatccgcgtgttcggca
 agccccagcggcaagcccgagttcgaggaggccgacccccgagaagctgcgcacctgctggccgagaagctgagcagccgccctga
 20 ggccgtgcagagtagtactcctgttctgtgagccgcgcccccaaccgcaagatgagcggtcagggtcacatggagaccgtgaagagc
 gccaaagcgcctggacgagggcgtagcgtgctgcgcgtgccccctgaccagctgaagctgaaggacctggagaagatggtgaaccgca
 gcgcgagcccaagctgtacgagccctgaaggcccgctggaggccacaaggacgaccccgccaaggccttcgccgagcccttctaca
 agtacgacaaggccggcaaccgacccagcaggtgaaggccgtgcgcgtggagcaggtgcagaagaccggcggtggtggtgcgaacca
 caacggcatcgccgacaacgccaccatggtgcgcgtggacgtgttcgagaaggcgacaagtactacctggtgccatctacagctggcag
 25 gtggccaaggcgatcctgcccgaccgcgccgtggtgcagggcaaggacgaggagactggcagctgatcgacgacagcttcaactcaag
 ttcagcctgcaccccaacgacctggtggaggtgatccaagaaggcccgatgttcggctacttcgccagctgccaccgcccacccggca
 acatcaacatccgcatccacgacctggaccacaagatcggaagaacggcatcctggaggcgatcgcggtgaagaccgccctgagcttcca
 gaagtaccagatcgacgagctgggcaaggagatccgccctgccgcctgaagaagcgcctcctgtgcgctaa [SEQ ID NO:1]
 NM-Cas9-Δ567-654
 30 atggccgcttcaagcccaaccccatcaactacatcctgggctggccatcgccatcgccagcgtgggctgggcatggtggagatcgacg
 aggacgagaaccccatctgctgatcgacctgggtgtgcgcgtgttcgagcgcgtgaggtgcccagactggtgacagttggtatggct
 cgccggcttgctcgtctgttcggcgcccttactgccggcgcgctcaccgcttctgcgcgctgccgctgtgaagcgcgaggggtgtgctg
 caggctgccgacttcgacgagaacggcctgatcaagagcctgcccaacactccttggcagctgcgcgctgccgctctggaccgcaagctga
 ctctcttgagtgaggcgcgctgctgctgcacctgatcaagcaccgcggctacctgagccagcgcaagaacgagggcgagaccgccgaca
 35 aggagctgggtgctctgtgaagggcgctggccgacaacgccacgccctgcagactggtgacttccgcactcctgctgagctggccctgaa
 caagttcgagaaggagagcggccacatccgcaaccagcgcggcgactacagccacacctcagccgcaaggacctgcaggccgagctga

tcctgctgttcgagaagcagaaggagttcggcaacccccacgtgagcggcggcctgaaggaggcgcagacacctgctgatgaccagc
 gccccgcctgagcggcgacgccgtgcagaagatgctgggccactgcaccttcgagccagccgagcccaaggccgccaagaacacctac
 accgccgagcgttcatctggctgaccaagctgaacaacctgcgcacacctggagcagggcagcgagcggccccctgaccgacaccgagcgc
 gccacctgatggagcagccctaccgcaagagcaagctgacctacgcccaggccccgaagctgctgggtctggaggacaccgcttcttca
 5 agggcctgcgctacggcaaggacaacgccgaggccagcaccctgatggagatgaaggcctaccacgccatcagccgcgcctggagaag
 gagggcctgaaggacaagaagagtctctgaacctgagccccgagctgcaggacgagatcggcaccgccttcagcctgttcaagaccgac
 gaggacatcaccggccgctgaaggaccgcatccagcccgagatcctggaggccctgctgaagcacatcagcttcgacaagttcgtgcaga
 tcagcctgaaggccctgcgccgcatcgtccccctgatggagcagggcgaagcgctacgacgaggcctgcgccgagatctacggcgaccact
 acggcaagaagaacaccgaggagaagatctacctgcctctatccccgccgacgagatccgaacccccgtgggtgctgcgcgcctgagcc
 10 agggccgcaagtgatcaacggcgtggtgcgccgctacggcagccccgcccgcacccatcgagaccgcccgcgaggtgggcaagag
 ctcaaggaccgcaaggagatcgagaagcgccaggaggagaaccgcaaggaccgcgagaaggccgcccaagtctcgcgagtaacttc
 ccaactcgtgggcgagcccaagagcaaggacatcctgaagctgcgcctgtacgagcagcagcacggcaagtgcTCCGGCGGGCG
 GTTCGcagaagttcgacgaggacggctcaaggagcgcgaacctgaacgacacccgctacgtgaaccgcttctgtccagttcgtggcc
 gaccgcatgcgcctgaccggcaagggaagaagcgctgttgcgccgaacggccagatcaccacacctgctgcgcggctctggggcctg
 15 cgcaaggtgcgcgccgagaacgaccgccaccacgccctggacgccgtggtggtggcctgcagcaccgtggccatgcagcagaagatcac
 ccgcttcgtgcgtacaaaggagatgaacgccttcgacggtaaaaccatcgacaaggagaccggcgaggtgctgcaccagaagaccacttc
 cccagccctgggagttcttcgccagggaggtgatgatccgcgtgttcggcaagcccacggcaagcccagttcgaggaggccgacacc
 cccgagaagctgcgcacctgctggccgagaagctgagcagccgcctgaggccgtgcacgagtagtactcctctgttcgtgagccgcg
 ccccaaccgcaagatgagcggtcagggtcacatggagaccgtgaagagcgccaagcgctggacgagggcgtagcgtgctgcgcgtg
 20 cccctgaccagctgaagctgaaggacctggagaagatggtgaaccgcgagcgcgagcccaagctgtacgagggcctgaaggccgcct
 ggaggcccaagacgacccccgcaaggccttcgccgagccctctacaagtacgacaaggccggcaaccgacccagcaggtgaagg
 ccgtgcgcgtggagcaggtgcagaagaccggcgtgtgggtgcgcaaccacaacggcatcggcgacaacgccaccatggtgcgcgtggac
 gtgttcgagaaggcgacaagtactacctggtccccatctacagctggcaggtggccaaggcgatcctgcccagccgcccgtgtgcag
 gcaaggacgaggaggactggcagctgatcgacgacagcttaactcaagttcagcctgcaccccaacgacctggtggaggtgatcacaa
 25 gaaggcccgatgttcggctacttcgccagctgccaccggcgaccggcaacatcaacatccgcatccacgacctggaccacaagatcgcc
 aagaacggcatcctggagggcacggcgtgaagaccgccctgagcttcagaagtaccagatcgacgagctgggcaaggagatccggccc
 tggccgctgaagaagcgccctcctgtgcgctaa [SEQ ID NO:2]

YFP reporter plasmid

agctctgaacccagagtcccgcctcagaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgataccgta
 30 aagcacgaggaagcggtcagccattcgccgccaagctcttcagcaatatcacgggtagccaacgctatgtctgatagcggctccgcacac
 ccagccggccacagtcgatgaatccagaaaagcgccattttccacctgatattcggcaagcaggcatcgccatgggtcacgacgagatcc
 tcgccgtcgggcatgcgcgcttgagcctggcgaaacgttcggctggcgcgagccccctgatgctcttcgtccagatcatcctgatcgacaaga
 ccggttccatccgagtagtgcctcgtgatgcgatgtttcgttgggtgaatggcgaggttagccggatcaagcgtagcagccggcgc
 attgcatcagccatgatggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccataagcagccagtcc
 35 ctccccgttcagtacaacgtcgagcacagctgcgcaaggaacggcgctggtggccagccagatagccgcgctgcctcgtcctgcagttc
 attcagggcaccggacaggtcggtcttgacaaaaaagaccggcgccccctgcgctgacagccggcaacacggcgccatcagagcagccga

ttgtctgttgtgcccagtcatagccgaatagcctctccaccaagcgggcgagaaacctgctgcaatccatcttgttcaatcatgcgaaacgat
cctcatcctgtctcttgatcagatcttgatccccctgcgccatcagatccttggcgggaagaaagccatccagttactttgcagggttcccaacct
taccagagggcgccccagctggcaattccgacgtctaagaaccattattatcatgacattaacctataaaaaataggcgtatcacgagggcccttt
cgtcttcacctcgaggggacaatgaaaacgttagtcatggcgcccttgacggctagctcagtcctaggtacagtgctagcttaatgctcgac
5 atagcagaactttaaaagtattcgccatgtttagtctccctttctcatttcgcagtgtacaaatccgccgctatggcccacgtagagcatacggaa
aaaaaagtcaaaagcctccgaccggaggtcgcccttacttgcctagcagagttttagaaaacgcaaaaaggccatccgtcaggatggccctctg
cttaatttgatgcctggcagtttatggcggcgctctgccgccacctccggggcgttgcttcgcaacgttcaaatccgtcccgggcgatttgc
cctactcaggagagcgttcaccgacaaacaacagataaaacgaaaggccagctttcgcactgagcctttcgtttttttagtgcctggcagttcc
ctactctcgcatggggagacccacactaccatcggcgtacggcggttacttctgagttcggcatggggcaggtgggaccaccgcgctac
10 tggccgacaggcaaatctgttttatcagaccgcttctgcgttctgatttaatctgtatcaggctgaaaatctctcatccgccaaaacagccccgt
agaaaaagggtgacgttgatggcgacgttaagaggtccacgataaatatcaacaccgtgcgtgttgactttttacctctggcggtgataatggtg
catgtactagaattctttaactttaagaaggagatatacatgaatccctatggcgaatacttttaagtcctgtaaaggagaagaacttttactg
gagttgtcccaattcttgaattagatgggtgatgtaatgggcacaaattttctgtagtgagaggggtgaagggtgatgaacatacggaaaaact
tacccttaaaatttatttcactactggaaaactacctgttccatggccaacactgtcactactttcggttatgggtctaaaatgctttgctagataccca
15 gatcatatgaaacggcatgacttttcaagagtgccatgcccgaagggtatgtacaggaaagaactatattttcaagatgacgggaactacaa
gacacgtgctgaagtcaagttgaagggtgatacccttgaatagaatcaggttaaaaggatttgaatttaagaagatggaacattcttgacac
aaattggaatacaactataactcacacaatgtatacatcatggcagacaaaagaatggaatcaaagtttaacttcaaaattagacacaacatt
gaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcctat
caatctgccctttcgaaagatcccaacgaaaagagagaccacatggctcttctgagtttgaacagctgctgggattacacatggcatggatga
20 actatacaaaatagcttaaccgaagcgttgatagttgatacctttgcctgcggccgcaactagaggcatcaataaaacgaaaggctcagtcg
aaagactgggcctttcgtttatctgttgttgcgtgaacgctctcctgagtaggacaaatccgccgccctagacctagggtacgggttttgcgtg
cccgcaaacgggctgttctggtgttgcctagttgttatcagaatcgcagatccggcttcaggttggccgctgaaagcgtatttctccagaattg
ccatgattttttcccacgggagggcgtcactggctcccgtgttgcggcagctttgattcgataagcagcatcgccgtttcaggctgtctatgtgt
gactgttgagctgtaacaagttgtctcaggtgttcaatttcatgttctagttgctttgttttactggttcacctgttctattaggtgttacatgctgttcac
25 tgttacattgtcgtatgttcatggtgaacagctttaaatgcacaaaaactcgtaaaagctctgatgtatctatctttttacaccgttttcatctgtgc
atatggacagttttccctttgatatacaggtgaacagttgttctacttttgtttgtagtcttgatgcttactgatagatacaagagccataagaacc
tcagatcctccgtatttagccagtatgttctctagtggtggtcgtttgtttgcgtgagccatgagaacgaaccattgagatcatgcttactttgcatgt
cactcaaaaaattttgcctcaaaactggtagctgaattttgcagttaaagcatcgtgtagtgttttcttagtccgttaccgtaggtaggaatctgatgt
aatgggtgttggtattttgtcaccattcattttatctggtgttctcaagttcggttacgagatccattgtctatctagttcaacttgaaaatcaacgta
30 tcagtcggggcgccctcgttatcaaccaccaatttcatattgctgtaagtgtttaaacttttacttattggtttcaaaacccattggttaagccttttaa
ctcatggttagttattttcaagcattaacatgaacttaattcatcaaggctaattctctatatttgccttgtagttttctttgtttagttcttttaataacca
ctcataaatctcatagatgattttgttttcaaaagacttaacatgttccagattatattttgaattttttaaactggaaaagataaggcaatatctcttca
ctaaaaactaatttcaatttttgccttgagaacttggcatagttgtccactggaaaatctcaaagcctttaaccaaaggattcctgatttccacagttc
tcgtcatcagctctctggttgccttagctaatacaccataaagcattttccctactgatgttcatcatctgagcgtattgggtataagtgaacgataccgt
35 ccgttcttctctgttaggggttttcaatcgtgggggttagtagtgccacacagcataaaattagcttgggttcatgctccgttaagtcatagcgactaat
cgctagttcatttgccttgaaaacaactaattcagacatacatctcaattggtctaggtgattttaatcactataccaattgagatgggctagtcattg

ataaataactagtccttttccctttgagttgtgggtatctgtaaattctgctagacctttgctggaaaactgttaaattctgtagacctctgtaaattccgc
tagacctttgtgtgtttttttgttatattcaagtgggtataatttatagaataaagaaagataaaaaagataaaagaatagatcccagccctgtgt
ataactcactacttttagtcagttccgcagttatfacaagagatgtcgaaacgctgtttgctcctctacaaaacagaccttaaacccctaaaggctt
aagtagcaccctcgcaagctcgggcaaatcgtgaatattcctttgtctccgaccatcaggcacctgagtcgctgtcttttcgtgacattcagttc
5 gctgcgctcacggctctggcagtgatgggggtaaatggcactacaggcgccctttatggattcatgcaaggaaactacccataatacaagaaa
agcccgtcacgggcttctcagggcgtttatggcgggtctgctatgtggtgctatctgactttttgctgttcagcagttcctgccctctgattttccag
tctgaccacttcggattatcccgtgacaggtcattcagactggctaattgcaccagtaaggcagcgggtatcatcaacaggttaccgtcttactg
tcctagtgttggttctcaccataaaaaacgcccggcggaaccgagcgttctgaacaaatccagatggagttctgaggtcattactggatc
tatcaacaggagtcgaagcg [SEQ ID NO:3].

10 According to the methods described herein, several deletions within NM-Cas9 have been identified, the largest NM-Cas9- Δ 255-449 removes 595 basepairs and shows only a 16% decrease in activity as measured by the reporter assay. According to certain aspects, mutant Cas9 proteins are provided which have 1000 fewer base pairs or 900 fewer base pairs compared to the wild type Cas9, such as NM-Cas9 and retain near wild-type levels of activity.

15 EXAMPLE II

Targeting Cas9 Nuclease Domains for Deletion

20 Along with targeting regions of low sequence conservation or between sequence conservation edges in the case where a nickase or nuclease null allele of Cas9 is desired, one can target the Cas9 nuclease domains along with their surrounding nucleotides for deletion. Utilizing such an approach, a functional NM-Cas9 allele lacking the HNH motif and surrounding nucleotides NM-Cas9- Δ 567-654 was made which retained near wild-type ability to bind DNA as determined by the YFP reporter assay.

Example III

25 Methods to Construct a Non-biased NM-Cas9 Deletion Library

30 Aside from taking a targeted approach to generating Cas9 deletions, aspects of the present disclosure include a high-throughput approach for random deletion creation and screening of functional mutants. According to an exemplary method, plasmid DNA containing the desired Cas9 allele can be sheared using a promiscuous nuclease, sonication, repeatedly pipetting the sample, or other chemical, enzymatic or environmental means. Once fragmented, the plasmid DNA can be treated with exonucleases to remove nucleotides from the Cas9 gene. After exonuclease treatment, fragmented ends are made blunt ended with enzymes such as Mung Bean nuclease or Klenow polymerase and ligated together to regenerate a Cas9 plasmid containing a random deletion. To

insert an exogenous domain such as a linker or effector motif within the deleted portion of Cas9, such domains can be ligated to the blunt ended fragmented DNA, and subsequent circularization of the plasmid will produce a Cas9 coding sequence where the exogenous domain has been inserted within the deleted portion of Cas9. The library of circularized molecules will then be transformed into *E. coli* and plasmid DNA will be extracted.

At this point, the library can be transformed into cells containing a reporter assay for Cas9 activity and members of the library that maintain functional activity can be identified. Alternatively, to reduce the size of the library to be screened, the coding sequence for Cas9 from the newly generated library can be isolated via digestion or PCR and the fragments can be size-selected to be shorter than the initial wild-type Cas9 gene. These smaller members can then be ligated back into the starting vector and transformed into cells containing the reporter of Cas9 activity.

Aside from plasmid shearing, a library of oligonucleotides can be generated that have 3' homology to the Cas9 gene but contain 5' homology to each other, where the 3' end of each oligonucleotide binds to a different stretch of around 30 basepairs within Cas9. These oligonucleotides cover both the sense and anti-sense strands of the Cas9 coding sequence. PCR can then be performed with these oligonucleotides to generate a series of Cas9 fragments with each product from a given sense PCR reaction having complementarity to all other anti-sense PCR products and vice-versa. These fragments can then be annealed together using methods such as Gibson assembly or overlap extension PCR followed by ligation into a vector backbone and transformed into cells, generating a library of Cas9 variants with random stretches of the Cas9 gene removed. For longer linkers or to insert an effector domain within the deleted regions, the oligonucleotides on their 5' ends should contain complementarity towards the longer linker or effector domain and this domain should then be included in the Gibson assembly reaction or during overlap extension PCR. Once a library has been generated, functional variants can be identified using a reporter assay such as the YFP reporter system described herein.

Example IV

Vector Construction

Cas9 nuclease null plasmids were ST1 (Addgene# 48659) or were constructed from plasmids NM and TD (Addgene# 48646 and 48648, respectively) by introducing the following point mutations (NM: D16A D587A H588A N611A and TD: D13A D878A H879A N902A). Cas9 deletions were generated using Gibson assembly. Internal deletions when made were joined by a 5 amino acid Ser-Gly-Gly-Gly-Ser linker, except for NM Δ 566-620 which lacks a linker between joined fragments. The N-terminal domain exchange fused residues 1-117 of ST1 onto residues

118-1082 of NM. The C-terminal domain exchange fused residues 1-727 of NM onto residues 743-1121 of ST1.

Example V

Bacterial Reporter Constructs

5

Reporter constructs used for analysis of the deletion mutants are similar to those previously published except they combine the spacer element and YFP reporter into a single SC101-kanR plasmid backbone. Reporter constructs for domain-exchange analysis are identical to those used previously. See Esvelt, K. M. *et al.* Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nature methods* 10, 1116-1121, doi:10.1038/nmeth.2681 (2013) hereby incorporated by reference in its entirety.

Example VI

Mammalian Reporter Constructs

15 M-ST1n-VP64 construct, ST1 guideRNA plasmid and ST1 specific mammalian transcriptional reporter were previously published in Esvelt, K. M. *et al.* Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nature methods* 10, 1116-1121, doi:10.1038/nmeth.2681 (2013) (Addgene# 48675, 48672 and 48678, respectively). Deletion mutants were made as in the bacterial constructs.

20

Example VII

Repression Assays

Cas9 repression assays were performed by co-transforming NEB 10-beta cells (New England BioLabs) with the appropriate spacer/reporter construct and Cas9 vector to be investigated. Colonies from transformations were picked and grown at 37°C with continuous shaking in 96 well plates. Plates were read the following day using a Synergy Neo microplate reader (BioTek), measuring fluorescence at 495–528 nm and absorbance at 600 nm. For swap experiments two different previously published spacer/protospacer combinations (A and B) (see Esvelt, K. M. *et al.* Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nature methods* 10, 1116-1121, doi:10.1038/nmeth.2681 (2013)) were tested. For all other experiments, only spacer/protospacer combination B was examined.

30

Example VIII

Cell Culture and Transfections

HEK 293T cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) with high glucose supplemented with 10% FBS (Invitrogen) and penicillin/streptomycin (Invitrogen). Cells were maintained at 37°C and 5% CO₂ in a humidified incubator. Cells were transfected in 24 well plates seeded with 50,000 cells per well. 400ng of Cas9 activator, 100ng of gRNA and 60ng of reporter plasmid were delivered to each well using 2.5 ul of Lipofectamine 2000. Cells were grown an additional 36-48 hours before being assays using immunofluorescence or FACS.

Example IX

Multiple Sequence Alignments and Edge Filter

Multiple sequence alignments were made by re-aligning Cas9 sequences in the PFAM database (PF13395, 798 sequences) in MUSCLE, and conditioning the alignment for diversity and full-length sequences using a MATLAB script. This method described in more detail below yielded 217 sequences.

In order to arrive at the final re-alignment of the Cas9 sequences in the PFAM database (PF13395, 798 sequences), the following steps (all program code in MATLAB) were carried out. The alignment from Fonfara I, *et al.*, (2014) Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems, *Nucleic Acids Res.* 42, 2577-90 was obtained and only sequences from group IIA and IIC were included, and from the latter only up to the branch that separates IIA and IIC (marked in red box in Fig. 2) which included 49 total sequences.

The sequences were then split into two groups, one with and one without the large insertion at approximately position 150 (which distinguishes e.g. between NM-Cas9 and ST-Cas9 on one hand and SP-Cas9 and TD-Cas9 on the other). These groups are separately aligned using MUSCLE (see Edgar, RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput, *Nucleic Acids Res* 32, 1792-97, re-aligned using a windowed approach (because of the length of the sequences), and then profile-profile aligned back into one seed alignment.

The sequences in PF13395 are realigned with MUSCLE and using the seed alignment. All alignments using a seed are performed by aligning each of the target sequences one-by-one to the seed. This alignment is used to determine the top-hit identity between seed and target sequences, which are re-ordered according to decreasing top-hit identity. The target sequences are then again aligned to the seed one-by-one, now in order of decreasing identity. This two-step approach is

taken to ensure the robustness of the alignment. Also these sequences are split depending on whether they contain the insertion or not, and the two separate groups are re-aligned with the seed as a profile. Short sequences and sequences with large truncations are removed manually. Sequences with higher than 90% pairwise similarity are removed.

5 The resulting two alignments are profile-profile aligned to each other which resulted in the 217 total sequences. The resulting alignments are truncated to the positions of the Cas9 ortholog of interest.

Sequence conservation was calculated as the relative entropy with respect to the background frequency of amino acids averaged over all genes in *Escherichia coli* O157. Domain boundary detection was performed by applying a Difference of Gaussians (DoG) edge filter (see 10 Marr, D. & Hildreth, E. Theory of edge detection. *Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character*. Royal Society 207, 187-217 (1980) hereby incorporated by reference in its entirety) to the resulting conservation profile, averaging over multiple length scales to achieve robustness to choice of parameters and detection at various length 15 scales.

In particular, the conservation of the alignment was calculated, being the relative entropy (see Cover, TM and Thomas, JT (2006) *Elements of Information Theory*; 2nd edition, Wiley-Interscience) of amino acid frequencies with respect to the average frequencies for all genes in *Escherichia coli* O157:

$$D_i = \sum_{a=1}^{20} p_i^a \log \frac{p_i^a}{q^a}$$

20 where p_i^a is the frequency of amino acid a at position i , and q^a is the average frequency of amino acid a . Summation is over all 20 amino acids. The log is base 2 and the entropy is given in bits. Average frequencies q^a are as follows:

{A C D E F G H I K L M N P Q R S T V W Y} = .094 .012 .052 .058 .038 .073 .022 .059 .045 25 .104 .027 .041 .044 .044 .057 .060 .055 .070 .015 .029. The Cas9 alignment yields the conservation profile in Fig. 3, after truncation to positions of NM-Cas9.

The conservation profile is plotted truncated to positions in SP-Cas9 (which is an example of the larger Cas9-proteins from the type IIA subfamily). Similar features are observed at the N-terminal approximately until position NM145(SP170) and then again after position 30 NM200(SP400), which is the large insertion described above. See Fig. 4.

Potential domain boundaries were identified by applying a multi-scale edge filter to the conservation profile. This filter calculates the difference of Gaussians (DoG) (see Marr, D and Hildreth, E (1980) *Theory of Edge Detection*, *Proc R Soc Lond B Biol Sci* 207, 187-217 hereby incorporated by reference in its entirety) for a range of scales and sums the resulting graphs. The

extrema of this curve are interpreted as the boundaries between lowly and highly conserved regions in the protein. Domains may exhibit different levels of conservation due to their potentially different functional importance leading to differential rates of evolutionary divergence. Differential conservation may be characteristic of a multi-domain protein that is the result of domain insertion over evolutionary timescales. The values of the extrema are used to rank-order the boundaries in terms of importance.

For the Cas9 alignment, restricted to NM positions, the following boundaries or conservation edges or edge amino acids were identified using the methods described herein:

	Rank	Position	Abs Val of Extremum
10	1	736	0.0225
	2	620	0.0148
	3	554	0.0148
	4	472	0.0144
	5	288	0.0136
15	6	144	0.0131
	7	87	0.0106
	8	661	0.0101
	9	825	0.0100
	10	205	0.0099
20	11	512	0.0092
	12	414	0.0092
	13	108	0.0092
	14	853	0.0067
	15	438	0.0050
25	16	936	0.0041
	17	1011	0.0038

Example X

Computational Analysis of Cas9 Family Members

In order to identify regions within the multi-domain Cas9 protein that may be amenable to deletion, a bioinformatics approach was used to identify potential boundaries between domains. Using a well-curated seed alignment, full-length Cas9 sequences from PFAM (PF13395) were realigned and sequences with high pairwise identity were removed as described above. The first-order sequence conservation was calculated as the relative entropy (see Cover, T. M., Thomas, J.T. *Elements of Information Theory, 2nd edition.* (Wiley-Interscience, 2006)) of observed amino acid

frequencies with respect to the average frequencies across all genes in *Escherichia coli*. As domains in a multi-domain protein can be expected to exhibit varying levels of sequence conservation, applying a multi-scale edge filter to the conservation profile may be used to identify locations of the domain boundaries.

Edge detection on the conservation profile was performed with a difference of Gaussians (DoG) band-pass filter that is sensitive to a narrow range of spatial frequencies. See Marr, D. & Hildreth, E. Theory of edge detection. *Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character*. Royal Society 207, 187-217 (1980). In order to allow detection at various length scales and to make the filter insensitive to a particular choice of parameters, an averaging over multiple scales (5-50 amino acids) was carried out. The band-pass filter was then applied to the conservation profile for the Cas9 alignment. The identified potential boundary positions for NM-Cas9 are shown in Fig. 5A, with the top 6 ranking boundaries in bold longer red lines. As can be seen, the filter correctly identifies the known HNH and RuvC domain arrangements that were assigned previously in Sapranaukas, R. *et al.* The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic acids research* 39, 9275-9282, doi:10.1093/nar/gkr606 (2011) and Fonfara, I. *et al.* Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic acids research* 42, 2577-2590, doi:10.1093/nar/gkt1074 (2014) each of which are incorporated by reference in its entirety (see Fig. 5B), starting upstream of position 500 and ranging until position 750. Boundaries between the domains, at around positions 560 and 620, are also correctly predicted. Also the boundary of the first arginine-rich alpha-helix at position 88 is predicted. One of the top-ranking boundaries on the N-terminal side of the protein, at position 144, was not identified as a domain boundary previously in Fonfara, I. *et al.* Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic acids research* 42, 2577-2590, doi:10.1093/nar/gkt1074 (2014), but represents a better delineation of the Arg-rich alpha-helical region, now including a second conserved arginine-rich helix.

Example XI

Truncation and Deletion Analysis of Cas9

To explore functional and potentially non-functional domains within Cas9 experimentally N and C-terminal truncations were generated, along with a set of modest internal deletions based upon the domain detection analysis described herein. The effects of the deletions were analyzed using a transcriptional repressor assay in *Escherichia coli*, in which a functional nuclease-null Cas9 protein will bind to the 5' end of a YFP reporter, thereby lowering its expression level (see Fig.

6A). See Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152, 1173-1183, doi:10.1016/j.cell.2013.02.022 (2013); Esvelt, K. M. *et al.* Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nature methods* 10, 1116-1121, doi:10.1038/nmeth.2681 (2013) and Bikard, D. *et al.* Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. *Nucleic acids research* 41, 7429-7437, doi:10.1093/nar/gkt520 (2013) each of which are hereby incorporated by reference in its entirety. None of the N- or C-terminal truncations were able to repress the reporter, while two internal deletions, NMA Δ 255-289 and NMA Δ 330-389, downstream and upstream of the boundary at position 288, along with an NMA Δ 566-620 deletion showed near wild-type levels of repression (Fig. 6B and Fig. 7). Several rounds of additional analysis were performed in which the deletions were iteratively expanded and the ability to repress the reporter (Fig. 6B) was assayed. Two large non-overlapping regions 254-449 and 567-654 (comprising 18% and 8% of the total length of the protein, respectively) were identified that could be removed with negligible loss in NM activity (Fig. 6C). As seen from the alignment, NM positions 254-449 represent a stretch of relatively low conservation, in a region of the protein that is specific to Cas9 proteins. Positions 567 to 654 represent the HNH domain, a domain known to be critical in Cas9 DNA catalysis but was found to be dispensable for DNA binding.

To corroborate that the regions removed from NM-Cas9 were not unique to NM but represent general regions that can be removed from other Cas9 family members, the corresponding deletions were generated within nuclease null-variants of *Streptococcus thermophilus* Cas9 (ST1) and *Treponema denticola* Cas9 (TD, GI:42525843) and their function with the transcriptional repression assay was measured (Fig. 8A and Fig. 9). Corresponding deletion mutants in both ST1 and TD showed activities similar to their wild-type counterparts, suggesting that the removed regions are dispensable for Cas9 DNA binding throughout the Cas9 phylogeny, even among more distant members within the type II-A subfamily such as TD.

The activity of the two largest functional deletions described herein were tested within ST1-Cas9 using a transcriptional activator assay (Fig. 8B). In agreement with the analysis within *E. coli*, both ST1 deletion mutants retained activity comparable to the wild-type protein when fused to the VP64 activation domain and targeted to a fluorescent reporter in human cells (Fig. 8C-8D). The larger of the two deletion mutants Δ 255-450 (ST1 numbering) generates a Cas9 gene that is 2,793 base pairs in size.

Example XII
Cas9 Doman Exchange

The Cas9 N- and C-terminal domains may play critical roles in crRNA:tracrRNA binding and/or PAM selectivity. To analyze activity, a series of domain exchange mutants between NM and ST1 were made, replacing the N and/or C terminus of NM with the homologous region from ST1. The chimeric proteins were then tested using the transcriptional reporter assay described herein altering the guideRNA and/or Cas9 specific PAM within the reporter to determine the influence of the domain exchanges on protein specificity (Fig. 10A). The exact positions for the domain swaps were determined based on domain boundary analysis: positions were selected that were as close as possible to the most significant N- and C-terminal boundaries identified (Fig. 5A), that were at the same time nearly fully conserved within the alignment (Fig. 10B). None of the N-terminal domain swaps between NM and ST1 endowed NM with novel properties, suggesting that the ST1 N-terminus is not modular but instead functions in context with other regions of ST1 that were not transferred (Fig. 10C-10F). The C-terminal exchange generated a NM-ST1 hybrid that was capable of interacting with the ST1 crRNA:tracrRNA complex and was further able to suppress a reporter with a ST1 specific PAM (Fig. 10E). This result was further validated with an additional ST1 specific reporter as shown in Fig. 11(A)-11(D).

Claims:

1. A method of making a mutant DNA binding protein comprising
identifying a first amino acid sequence of either high conservation or low conservation
5 which is flanked by two flanking amino acid sequences of either low conservation or high
conservation, respectively, within a family of DNA binding proteins,
identifying a nucleic acid sequence for the first amino acid sequence,
generating a nucleic acid sequence for a target DNA binding protein which lacks the
nucleic acid sequence for the first amino acid sequence, and
10 generating a mutant DNA binding protein from the generated nucleic acid sequence.
2. The method of claim 1 wherein the target DNA binding protein has nuclease
activity.
- 15 3. The method of claim 1 wherein the target DNA binding protein is a nickase.
4. The method of claim 1 wherein the target DNA binding protein is nuclease null.
5. The method of claim 1 wherein the nucleic acid sequence for the first amino acid
20 sequence is deleted from a nucleic acid sequence for the target DNA binding protein.
6. The method of claim 1 wherein the nucleic acid sequence for the first amino acid
sequence is deleted from a nucleic acid sequence for the target DNA binding protein and replaced
with a linker.
25
7. The method of claim 1 wherein the nucleic acid sequence for the first amino acid
sequence is deleted from a nucleic acid sequence for the target DNA binding protein and replaced
with a SGGGS linker.
- 30 8. The method of claim 1 wherein the DNA binding protein is a Cas9 protein.
9. The method of claim 1 wherein the first amino acid sequence has a pair of edge
amino acid sequences distinguishing the first amino acid sequence from flanking amino acid
sequences.
35
10. A mutant Cas9 protein of SEQ ID NO:1.

11. A mutant Cas9 protein of SEQ ID NO:2.

12. A method of making a mutant Cas9 protein comprising
5 identifying one or more amino acid sequences within a family of Cas9 proteins that are not highly conserved or have low conservation,
identifying a nucleic acid sequence for the one or more identified amino acid sequences,
generating a nucleic acid sequence for a target Cas9 protein which lacks the nucleic acid
sequence for the one or more identified amino acid sequences, and
10 generating a mutant Cas9 protein from the generated nucleic acid sequence.

13. The method of claim 12 wherein the target Cas9 protein has nuclease activity.

14. The method of claim 12 wherein the target Cas9 protein is a nickase.

15. The method of claim 12 wherein the target Cas9 protein is nuclease null.

16. The method of claim 12 wherein the nucleic acid sequence for the one or more
identified amino acid sequences is deleted from a nucleic acid sequence for the target Cas9 protein.

17. The method of claim 12 wherein the nucleic acid sequence for the one or more
identified amino acid sequences is deleted from a nucleic acid sequence for the target Cas9 protein
and replaced with a linker.

18. The method of claim 12 wherein the nucleic acid sequence for the one or more
identified amino acid sequences is deleted from a nucleic acid sequence for the target Cas9 protein
and replaced with a SGGGS linker.

19. A method of making a mutant Cas9 protein comprising
30 replacing a C terminal domain from a first Cas9 protein species with a C terminal
domain from a second Cas9 protein species.

20. The method of claim 19 wherein the first Cas9 protein species is NM-Cas9 and the
second Cas9 protein species is ST1-Cas9.

21. A method of making a chimeric Cas9 protein comprising

replacing an N terminal domain from a first Cas9 protein species with an N terminal domain from a second Cas9 protein species.

22. The method of claim 21 wherein the first Cas9 protein species is NM-Cas9 and the
5 second Cas9 protein species is ST1-Cas9.




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D






FIG. 3




FIG. 5A











FIG. 5B





10/14








FIG. 10A





FIG. 10B



NM-Cas9 PAM:
AAAAGATT

ST1-Cas9 PAM:
AAAGAAATT

FIG. 10C NM gRNA with NM reporter PAM




FIG. 10D NM gRNA with ST1 reporter PAM




FIG. 10E ST1 gRNA with NM reporter PAM




FIG. 10F

ST1 gRNA with NM reporter PAM




FIG. 11A




FIG. 11B



FIG. 11C





FIG. 11D



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 14/66375

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - C12N 15/00, 9/16; C07K 1/00; C07H 21/04 (2015.01) CPC - C12N 15/02, 9/16, 15/52; C07K 2319/00 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) CPC: C12N 15/02, 9/16, 15/52; C07K 2319/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched CPC: C12N 15/02, 9/16, 15/52; C07K 2319/00 (text search) USPC: 435/440, 196; 183, 252.3; 530/350; 536/23.2. 23.4 (text search)				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Electronic data bases: PatBase, Google Scholar; Google Patents; GenCore sequence search (AA) Search terms: Cas9 (synonym: Csn1), nuclease, nickase, null nuclease (dCas9), RuvC-like domain, HNH nuclease domain, ortholog, dominant negative deletion, domain swapping, deletion mutant, chimeric, S. pyrogenes (SP), S. thermophilus (ST), N. meningitidis				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X — Y	VAN LEEUWEN et al. Linker length and composition influence the flexibility of Oct-1 DNA binding. EMBO J 15 April 1997 Vol 2043-2053. Especially abstract, pg 2043 col 2 para 2, pg 2044 fig 1B.	1, 4-6, 9 — 2, 3, 7, 8, 12-18		
Y — A	CHYLINSKI et al. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol May 2013 Vol 10 No 5 Pages 726-737. Especially 727 col 1 para 1, pg 727 col 2 para 2, Suppl Fig S1.	2, 3, 8, 12-18 — 19-22		
Y	US 2011/0286980 A1 (BRENNER) 24 November 2011 (24.11.2011). Especially sheet 36 fig 25.	7, 18		
Y	MALI et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology ePub 1 August 2013 Vol 31 No 9 Pages 833-838. Especially pg 5 para 4, Suppl Fig S15.	3, 14, 15		
A	ZHOU et al. Alteration of substrate specificities of thermophilic alpha/beta hydrolases through domain swapping and domain interface optimization. Acta Biochim Biophys Sin December 2012 Vol 44 No 12 Pages 965-973. Especially abstract.	19-22		
A	ESVELT et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nature Methods Epub 29 September 2013 Vol 10 No 11 Pages 1116-1121. Especially pg 1 col 2 para 4.	19-22		
X,P	US 2014/0242700 A1 (ZHANG et al.) 28 August 2014 (28.08.2014). Especially para [0011]).	19, 21		
☐ Further documents are listed in the continuation of Box C. ☐				
* Special categories of cited documents: <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 06 April 2015 (06.04.0215)	Date of mailing of the international search report 17 APR 2015			
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/66375

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☐ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
 - ☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☒ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.4.1 SEQ ID NOs: 1, 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/66375

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
 -----Go to Extra Sheet for continuation-----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-9, 12-22

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/66375

Continuation of Box III (Lack of Unity of Invention)

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: Claims 1-9, 12-22, drawn to a method of making a mutant binding protein, where the mutant binding protein may be a mutant Cas9 protein.

Group II: Claim 10, drawn to a mutant Cas9 protein of SEQ ID NO: 1

Group III: Claim 11, drawn to a mutant Cas9 protein of SEQ ID NO: 2

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I has the special technical features of particular method steps for making a mutant binding protein, not required by Groups II or III.

Groups II and III have the special technical feature of being a composition, not required by Group I.

Group II has the special technical feature of SEQ ID NO: 1, not required by Group III.

Group III has the special technical feature of SEQ ID NO: 2, not required by Group II.

Common Technical Feature:

Groups I-III share the special technical feature of a mutant DNA binding protein, where the protein may be a mutant Cas9 protein.

However, said common technical feature does not represent a contribution over the prior art, and is anticipated by the publication titled "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering" by MALI et al. (hereinafter "Mali") [Nature Biotechnol ePub 1 August 2013 Vol 31 No 9 Pages 833-838 and Supplementary Fig 1].

Mali teaches a mutant Cas9 DNA binding protein (pg 2 para 1-2; "By searching for sequences with known structure that are homologous to Cas9 (refer Supplementary Note 1), we identified and mutated up to 4 amino acids likely involved in magnesium coordination (Supplementary Fig. 1a). The generated quadruple Cas9 mutant showed undetectable nuclease activity upon deep sequencing at the targeted loci (Supplementary Fig. 1b), implying that we had successfully reduced Cas9 nuclease activity to levels below the threshold of detection in our assay. Nuclease-deficient Cas9 (hereafter referred to as Cas9N-) can in principle localize transcriptional regulatory domains to targeted loci by fusing these domains to either Cas9Nor to the sgRNA. We explored both approaches in parallel (Figs. 1a, 1b); pg PDF 17 Supple Fig 1; Supplementary Fig.1 Generation of nuclease deficient Cas9. (a) Metal coordinating residues in known protein structures with homology to Cas9. Residues are labeled based on position in Cas9 sequence" [mutants D10A, D10A H840A, D10A D839A H840A, D10A D839A H840A N863A indicated].

As the common technical feature was known in the art at the time of the invention, this cannot be considered a common special technical feature that would otherwise unify the groups. The inventions lack unity with one another.

Therefore, Groups I-III lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature